NCT02674763View on ClinicalTrials.gov

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

July 31, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

IMGN779

Trial Locations (7)

14263

Roswell Park Cancer Institute, Buffalo

35294

Comprehensive Cancer Center (UAB CCC), Birmingham

75246

Baylor Scott & White University Medical Center, Dallas

77030

The University of Texas, MD Anderson Cancer Center, Houston

87106

New Mexico Cancer Care Alliance, Albuquerque

97239

Knight Cancer Institute - OSHU, Portland

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT02674763 - Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter